SIMEDHealth’s Post

Good Opportunity

Human Organ Chips are revolutionizing drug discovery and toxicology testing as ethical alternatives to animal models. Read more about this innovative technology in the review article from the Wyss Institute at Harvard University, published in Pharmacology Research & Perspectives : https://lnkd.in/gSh_CzMa #OrganChips #DrugDiscovery #ToxicologyTesting #AnimalAlternatives #InnovativeTechnology #BiomedicalEngineering #PharmacologyResearch #Pharmacology

SoHo™ Telemetry System: DSI's New Evolution of Preclinical Implants for Temperature and Activity Infectious Disease • Measure temperature to better understand the effects of drug therapy and disease. • Confidently acquire real-time data from challenging Biological Safety Level (BSL) environments with a miniature hardware footprint. • Areas include vaccine development, fever, and trigger-to-treat studies. Neuroscience • Conduct longitudinal studies with the same subject; allowing for quantification of behavioral and physiologic change over time. • Add quantitative analysis of endpoints to studies. • Monitor temperature and activity in behavioral assays such as treadmills, mazes, and operant conditioning boxes. • Areas include stress and pain, and social behavior. Other Areas of Concentration • Basic Research • Hibernation and torpor • Exercise • Thermoregulation • Circadian Rhythm • Oncology • Reproductive studies Safety • Drug Development • Metabolism • Environmental • Toxicology #SoHoTelemetrySystem #Toxicology #researchscience #preclinicalimplants #SOT2024 #ToxExpo

🔬 Exciting Developments in Toxicology: The Role of Non-Parenchymal Cells 🔬 Hello LinkedIn community, Today, we want to shed light on a fascinating area of toxicological research that’s gaining significant momentum: the use of non-parenchymal cells (NPCs). NPCs, including stellate cells, Kupffer cells, and sinusoidal endothelial cells, play a pivotal role in liver physiology and pathology. In toxicological studies, understanding their behavior is crucial for a more holistic view of drug-induced liver injury (DILI). Here’s why NPCs are so vital: Multi-faceted Functions: Unlike parenchymal hepatocytes, NPCs participate in immune responses, fibrosis, and the formation of the liver's microenvironment. Improved Predictive Models: Incorporating NPCs into liver models offers a more accurate prediction of hepatotoxicity, enhancing drug safety assessments. Biomarker Discovery: Studying NPCs helps identify new biomarkers for early detection of liver injuries, crucial for both clinical and pharmaceutical advancements. The integration of NPCs in in vitro models is revolutionizing how we perceive drug metabolism and hepatotoxicity. It's not just about hepatocytes anymore; NPCs are proving to be key players in liver toxicology. Let's discuss: How can we further integrate NPCs into current toxicological research models? What are the challenges and opportunities in NPC-based research? Excited to hear your thoughts and insights! #Toxicology #LiverResearch #NonParenchymalCells #DrugSafety #Pharmacology #BiomedicalResearch

The combination of isogenic hepatocytes and NPCs in research models offers a more comprehensive approach to studying liver diseases and drug-induced liver injury (DILI). This integrative method enhances our understanding of liver biology and pathology, leading to better predictive models for drug safety and more effective therapeutic strategies. #Toxicology #LiverResearch #NonParenchymalCells #DrugSafety #Pharmacology #BiomedicalResearch

Nyrada today released its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2024 providing an update on the Company’s development programs and progress. During the quarter, Nyrada announced the results of a preclinical stroke study which assesses the efficacy of its lead Brain Injury Program candidate NYR-BI03. The study produced a strong signal of neuroprotective efficacy. MRI brain imaging showed statistically significant (p value 0.021) neuroprotection was achieved when animals received the NYR-BI03 treatment. On average, NYR-BI03 therapy rescued 42% of the brain injury in the penumbra region seen in animals receiving vehicle. Good Laboratory Practice (GLP) studies to assess the safety of NYR-BI03 in two animal species commenced late in the quarter. Elements of these GLP studies include but are not limited to cardiac safety, pharmacology, and toxicology tests. The Company also successfully completed a capital raise in the amount $1.76 million (before costs) in March 2024. A further $0.21 million (before costs) is expected to be received in May 2024 following the Company’s Extraordinary General Meeting where shareholder approval will be sought for the issue of CDIs to Nyrada non-executive directors on the same terms as those in the March 2024 capital raise ($0.075 per CDI). As at 31 March 2024, Nyrada had a cash position of A$5.60 million. To access a full copy of the announcement, please click on the following link: https://bit.ly/49xdqdu

# Leveraging Drosophila melanogaster in Biomedical Research 🧬✨ Drosophila melanogaster is a potent preclinical model due to its short life cycle and cost-effective maintenance. With ∼75% homology to human disease-related genes, it has become a game-changer in innovative approaches for evaluating candidate molecules. The fruit-fly model serves as an invaluable tool to expedite functional research, shedding light on the intricate mechanisms underlying different diseases. 📲 Contact us or schedule a meeting here https://lnkd.in/dD9wkEPJ to learn more about our models (DMD, liver disease, diabetes, ocular disease, IBD, Tox and much more). 🛩 Let's accelerate progress in understanding pathologies and advancing biomedical knowledge with the powerful Drosophila model! 🚀🧠 #Drosophila #preclinical #metabolicsyndrome #diabetes #toxicology #pharmacology #servicesolutions #outsourcing #preclinicalmanager Pasquale Cocchiaro PhD, MBA

📲 Contact us to learn more about our Drosophila models (DMD, liver disease, diabetes, ocular disease, IBD, Tox and much more). 🛩 Let's accelerate progress in understanding pathologies and advancing biomedical knowledge with the powerful Drosophila model! 🚀🧠 #Drosophila #preclinical #metabolicsyndrome #diabetes #toxicology #pharmacology #servicesolutions #outsourcing #preclinicalmanager PreClinic Pharmacology Services

Clinical Laboratory Services Market Size, Share & Trends Analysis Report By Specialty (Clinical Chemistry Testing {Routine Chemistry Testing, Endocrinology Chemistry Testing, Therapeutic Drug Monitoring (TDM) Testing, Specialized Chemistry Testing, Other Clinical Chemistry Testing}, Microbiology Testing {Infectious Disease Testing, Transplant Diagnostic Testing, Other Microbiology Testing}, Hematology Testing, Immunology Testing, Cytology Testing, Genetic Testing, Drug of Abuse Testing), By Provider (Independent and Reference Laboratories, Hospital-based Laboratories, Nursing and Physician Office-based Laboratories), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 Get A Sample Copy of This Report: https://lnkd.in/dQBdpcan Top Players/Manufacturers: A.P. Moller Holding Unilabs Abbott ACM MEDICAL LABORATORY INC-LONG POND Agena Bioscience Alere Toxicology Plc. AlSalam Specialist Hospital amedes-Gruppe American Medical Laboratories ARUP Laboratories Asuragen. BD Big South Fork Medical Center Bio-Rad Laboratories Biocept, Inc. bioMérieux Bio Reference Laboratories Inc CENTOGENE CERBA HEALTHCARE Charles River Laboratories Clinical Laboratory Services, Inc. Clinical Pathology Laboratories Southeast Clinical Reference Laboratory. DaVita HealthCare Partners DaVita Kidney Care Diversified Medical Healthcare Doctors Connection DOCTORS LAB - Independent Clinical Laboratory Enzo Biochem Inc Enzo Life Sciences, Inc. Eurofins Scientific Finland Oy Evexia Diagnostics Exosome Diagnostics. F. Hoffmann-La Roche Ltd Fresenius Medical Care GC Cell Genoptix, Inc. Genova Diagnostics GRAIL Great Ormond Street Hospital for Children NHS Foundation Trust

#IATDMCT2024 is almost here! Have you registered yet? 💡 Our program begins with a pre-congress symposium focused on New Frontiers in Clinical Toxicology. In today’s environment, the toxic drug supply constitutes a public health crisis. We will be exploring topics that bring that crisis to light such as wastewater testing (mirroring that which was in place for Covid19 testing); the use of artificial intelligence to help predict and test for novel psychoactive substances that may contribute to the toxic drug supply; we will discover what we can learn from a drug checking service and how that can inform clinical toxicology testing; and we will explore the proliferation of the semi-synthetic cannabinoids.  🎤 Our plenary speakers will offer insights into their respective fields as we explore precision medicine in cancer treatment, the use of psychedelics in psychiatry and health issues of first nations peoples. The Scientific Committee chairs have been working on your behalf to put together symposia that will dive into cutting-edge topics, offering a comprehensive look at the latest advancements in the field. Engage with your colleagues at one or two breakfast roundtables and discuss a topic of mutual interest. 🌐Learn more about our program online here: